Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2005 Aug;97(8):1120–1126.

Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis.

Nehir Samanci 1, Sebahat Ozdem 1, Halide Akbas 1, Derya Mutlu 1, Meral Gultekin 1, Mehmet Arman 1, Levent Donmez 1
PMCID: PMC2575986  PMID: 16173327

Abstract

OBJECTIVES: To investigate the prevalence of anticyclic citrullinated peptide (anti-CCP) in patients with advanced rheumatoid arthritis (RA) and to compare it with those in control subjects. Further, to study the relation between the anti-CCP and the disease activity parameters in these patients. PATIENTS AND METHODS: Seventy-six RA patients who had a mean disease duration of 9.8 years were included. Eighty-three age-matched non-RA volunteers were enrolled as the control group. Disease duration, duration of morning stiffness, swollen and tender joint counts, hand deformity, patient's assessment of pain, anti-CCP, rheumatoid factor (RF) and acute phase proteins were evaluated. The functional disability was also assessed with the Modified Health Assessment Questionnaire (HAQ). RESULTS: Thirty-seven sera (48.7%) in the patient group and one serum (1.2%) in the control group were positive for anti-CCP. RF was positive in 45% of the RA cases and in 5% of controls. Sensitivity and specificity of anti-CCP reactivity for RA were 49.0% and 99.0%, respectively. HAQ score and duration of morning stiffness were found to be significantly associated with anti-CCP positivity. Disease duration, swollen joint count and anti-CCP positivity were the most important variables predicting hand deformity. CONCLUSION: The prevalence, sensitivity and specificity of anti-CCP in patients with advanced RA were found to be similar to those reported in patients with early disease. Anti-CCP was significantly associated with some parameters of both disease activity and severity. Anti-CCP might be a useful parameter in clinical evaluation of patients with advanced RA.

Full text

PDF
1120

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend William P. Arthritis & Rheumatism in 2000. Arthritis Rheum. 2000 Jan;43(1):1–3. doi: 10.1002/1529-0131(200001)43:1<1::AID-ANR1>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Bas S., Genevay S., Meyer O., Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003 May;42(5):677–680. doi: 10.1093/rheumatology/keg184. [DOI] [PubMed] [Google Scholar]
  4. Bas S., Perneger T. V., Seitz M., Tiercy J-M, Roux-Lombard P., Guerne P. A. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002 Jul;41(7):809–814. doi: 10.1093/rheumatology/41.7.809. [DOI] [PubMed] [Google Scholar]
  5. Bizzaro N., Mazzanti G., Tonutti E., Villalta D., Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001 Jun;47(6):1089–1093. [PubMed] [Google Scholar]
  6. Bongi Susanna Maddali, Manetti Roberto, Melchiorre Daniela, Turchini Stefano, Boccaccini Piero, Vanni Lorenzo, Maggi Enrico. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity. 2004 Sep-Nov;37(6-7):495–501. doi: 10.1080/08916930400011965. [DOI] [PubMed] [Google Scholar]
  7. Davis P., Stein M., Ley H., Johnston C. Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann Rheum Dis. 1989 Jan;48(1):73–76. doi: 10.1136/ard.48.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Rycke L., Peene I., Hoffman I. E. A., Kruithof E., Union A., Meheus L., Lebeer K., Wyns B., Vincent C., Mielants H. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004 Dec;63(12):1587–1593. doi: 10.1136/ard.2003.017574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Rycke L., Verhelst X., Kruithof E., Van den Bosch F., Hoffman I. E. A., Veys E. M., De Keyser F. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2004 May 27;64(2):299–302. doi: 10.1136/ard.2004.023523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dörner Thomas, Egerer Karl, Feist Eugen, Burmester Gerd R. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004 May;16(3):246–253. doi: 10.1097/00002281-200405000-00013. [DOI] [PubMed] [Google Scholar]
  11. Enzer Ian, Dunn Graham, Jacobsson Lennart, Bennett Peter H., Knowler William C., Silman Alan. An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians: evidence of a decline due to both secular and birth-cohort influences. Arthritis Rheum. 2002 Jul;46(7):1729–1734. doi: 10.1002/art.10360. [DOI] [PubMed] [Google Scholar]
  12. Forslind K., Ahlmén M., Eberhardt K., Hafström I., Svensson B., BARFOT Study Group Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004 Sep;63(9):1090–1095. doi: 10.1136/ard.2003.014233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Genevay S., Hayem G., Verpillat P., Meyer O. An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis. Ann Rheum Dis. 2002 Aug;61(8):734–736. doi: 10.1136/ard.61.8.734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goldbach-Mansky R., Lee J., McCoy A., Hoxworth J., Yarboro C., Smolen J. S., Steiner G., Rosen A., Zhang C., Ménard H. A. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000 Mar 31;2(3):236–243. doi: 10.1186/ar93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hayward R. A., Shapiro M. F., Oye R. K. Laboratory testing on cerebrospinal fluid. A reappraisal. Lancet. 1987 Jan 3;1(8523):1–4. doi: 10.1016/s0140-6736(87)90698-2. [DOI] [PubMed] [Google Scholar]
  16. Houssien D. A., Jonsson T., Davies E., Scott D. L. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. J Rheumatol. 1997 Nov;24(11):2119–2122. [PubMed] [Google Scholar]
  17. Houssien D. A., Jónsson T., Davies E., Scott D. L. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand J Rheumatol. 1998;27(1):46–53. doi: 10.1080/030097498441173. [DOI] [PubMed] [Google Scholar]
  18. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004 Sep;63(9):1085–1089. doi: 10.1136/ard.2003.016808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kirstein H., Mathiesen F. K. Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scand J Rheumatol. 1987;16(5):331–338. doi: 10.3109/03009748709102504. [DOI] [PubMed] [Google Scholar]
  20. Knijff-Dutmer E., Drossaers-Bakker W., Verhoeven A., van der Sluijs Veer G., Boers M., van der Linden S., van de Laar M. Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis. 2002 Jul;61(7):603–607. doi: 10.1136/ard.61.7.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Korpilähde T., Heliövaara M., Kaipiainen-Seppänen O., Knekt P., Aho K. Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis. Ann Rheum Dis. 2003 Apr;62(4):353–355. doi: 10.1136/ard.62.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kükdeveci Ayse A., Sahin Hülya, Ataman Sebnem, Griffiths Bridget, Tennant Alan. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004 Feb 15;51(1):14–19. doi: 10.1002/art.20091. [DOI] [PubMed] [Google Scholar]
  23. Lindqvist E., Eberhardt K., Bendtzen K., Heinegård D., Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2004 Sep 30;64(2):196–201. doi: 10.1136/ard.2003.019992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lucey M. D., Newkirk M. M., Neville C., Lepage K., Fortin P. R. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol. 2000 Feb;27(2):319–323. [PubMed] [Google Scholar]
  25. Mallya R. K., Young B. J., Pepys M. B., Hamblin T. J., Mace B. E., Hamilton E. B. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol. 1983 Jan;51(1):17–20. [PMC free article] [PubMed] [Google Scholar]
  26. Meyer O., Labarre C., Dougados M., Goupille Ph, Cantagrel A., Dubois A., Nicaise-Roland P., Sibilia J., Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003 Feb;62(2):120–126. doi: 10.1136/ard.62.2.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mikuls T. R., O'Dell J. R., Stoner J. A., Parrish L. A., Arend W. P., Norris J. M., Holers V. M. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004 Dec;50(12):3776–3782. doi: 10.1002/art.20659. [DOI] [PubMed] [Google Scholar]
  28. Nielen Markus M. J., van Schaardenburg Dirkjan, Reesink Henk W., van de Stadt Rob J., van der Horst-Bruinsma Irene E., de Koning Margret H. M. T., Habibuw Moud R., Vandenbroucke Jan P., Dijkmans Ben A. C. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004 Feb;50(2):380–386. doi: 10.1002/art.20018. [DOI] [PubMed] [Google Scholar]
  29. Padyukov Leonid, Silva Camilla, Stolt Patrik, Alfredsson Lars, Klareskog Lars. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004 Oct;50(10):3085–3092. doi: 10.1002/art.20553. [DOI] [PubMed] [Google Scholar]
  30. Palosuo T., Tilvis R., Strandberg T., Aho K. Filaggrin related antibodies among the aged. Ann Rheum Dis. 2003 Mar;62(3):261–263. doi: 10.1136/ard.62.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pinheiro Geraldo Castelar, Scheinberg Morton A., Aparecida da Silva Miriam, Maciel Suely. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 2003 Aug 5;139(3):234–235. doi: 10.7326/0003-4819-139-3-200308050-00021. [DOI] [PubMed] [Google Scholar]
  32. Pope R. M., Lessard J., Nunnery E. Differential effects of therapeutic regimens on specific classes of rheumatoid factor. Ann Rheum Dis. 1986 Mar;45(3):183–189. doi: 10.1136/ard.45.3.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schellekens G. A., de Jong B. A., van den Hoogen F. H., van de Putte L. B., van Venrooij W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998 Jan 1;101(1):273–281. doi: 10.1172/JCI1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Scott D. L., Dawes P. T., Collins M., Stone R. ELISA assays for IgM and IgG rheumatoid factors: their clinical correlations during therapy with slow-acting anti-rheumatic drugs. Clin Rheumatol. 1987 Sep;6(3):358–368. doi: 10.1007/BF02206834. [DOI] [PubMed] [Google Scholar]
  35. Suzuki K., Sawada T., Murakami A., Matsui T., Tohma S., Nakazono K., Takemura M., Takasaki Y., Mimori T., Yamamoto K. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol. 2003;32(4):197–204. doi: 10.1080/03009740310003677. [DOI] [PubMed] [Google Scholar]
  36. Söderlin M. K., Kastbom A., Kautiainen H., Leirisalo-Repo M., Strandberg G., Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol. 2004;33(3):185–188. doi: 10.1080/03009740310004856. [DOI] [PubMed] [Google Scholar]
  37. Vallbracht I., Rieber J., Oppermann M., Förger F., Siebert U., Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004 Sep;63(9):1079–1084. doi: 10.1136/ard.2003.019877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vasiliauskiene L., Wiik A., Høier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis. 2001 May;60(5):459–466. doi: 10.1136/ard.60.5.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zeng Xiaofeng, Ai Maixing, Tian Xinping, Gan Xiaodan, Shi Yanping, Song Qinfang, Tang Fulin. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol. 2003 Jul;30(7):1451–1455. [PubMed] [Google Scholar]
  40. van Boekel Martinus A. M., Vossenaar Erik R., van den Hoogen Frank H. J., van Venrooij Walther J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2001 Nov 6;4(2):87–93. doi: 10.1186/ar395. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES